Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.32 USD 3.39%
Market Cap: 536.8m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Change in Working Capital
-$7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-68%
Bausch Health Companies Inc
TSX:BHC
Change in Working Capital
-$47m
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
21%
Canopy Growth Corp
TSX:WEED
Change in Working Capital
-CA$3.6m
CAGR 3-Years
N/A
CAGR 5-Years
67%
CAGR 10-Years
-15%
Sundial Growers Inc
NASDAQ:SNDL
Change in Working Capital
-CA$19.3m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Change in Working Capital
$11.2m
CAGR 3-Years
113%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Change in Working Capital
$133.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
536.8m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
2.22 USD
Overvaluation 70%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Change in Working Capital?
Change in Working Capital
-7m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Change in Working Capital amounts to -7m USD.

What is Mind Medicine (MindMed) Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-68%

Back to Top